OLX301D

**OLX301D** is an investigational RNAi therapeutic developed by OliX Pharmaceuticals using proprietary asymmetric siRNA (asiRNA) technology to silence connective tissue growth factor (CTGF) mRNA. It targets subretinal fibrosis and neovascularization in wet age-related macular degeneration (wet AMD), addressing unmet needs in choroidal neovascularization and disciform scarring that cause vision loss via macular edema and retinal detachment. Preclinical studies in animal models demonstrated efficacy in inhibiting fibrosis progression and showed comparable effects to existing anti-VEGF therapies, positioning it as a potential first-in-class treatment for combination or non-responsive patients.[1][3][7][9]